Anavex Life Sciences Announces Successful Development of Once-Daily Oral Tablet Formulation for the ANAVEX®3-71 Program

Core Insights - Anavex Life Sciences Corp. has successfully developed a once-daily oral tablet formulation for the ANAVEX3-71 program, demonstrating safety and tolerability in a Phase 1b clinical trial [1][2][3] Group 1: Product Development - The new modified-release oral tablet of ANAVEX3-71 shows superior pharmacokinetics compared to the immediate-release oral capsule, allowing for once-daily dosing [1][2] - The Phase 1b clinical trial (ANAVEX3-71-002) confirmed the pharmacokinetic profile supportive of once-daily dosing and consistent safety profile with prior studies [2][3] Group 2: Mechanism of Action - ANAVEX3-71 is a dual SIGMAR1 receptor agonist and M1 positive allosteric modulator, which has the potential to treat all symptom domains of schizophrenia without the side effects associated with standard antipsychotics [3][4] - The drug candidate has shown beneficial effects on mitochondrial dysfunction and neuroinflammation in preclinical trials, indicating its potential for treating Alzheimer's disease and other CNS disorders [4]